Monoclonal and polyclonal antibodies used in this study
| Primary antibody | Dilution | Source |
|---|---|---|
| Location of manufacturers: Dako, CA, USA; R & D Systems Europe Ltd, Abingdon, UK; PeproTech Inc, Rocky Hill, NJ, USA; Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA; PharMingen, San Diego, CA, USA. | ||
| PARC = pulmonary and activation regulated chemokine; MDC = macrophage derived chemokine. | ||
| Anti-CD3 (UCHT1) (mc) | 1:400 | Dako |
| Anti-PARC (64507) (mc) | 1:50 | R & D Systems |
| Anti-PARC (pc) | 1:50 | Pepro Tech Inc |
| Anti-MDC (pc) | 1:10 | Pepro Tech Inc |
| Anti-I-309 (35305.11) (mc) | 1:50 | R & D Systems |
| Anti-CCR4 (H-48) (pc) | 1:20 | Santa Cruz Biotechnology, Inc |
| Anti-CD25 (ACT-1) (mc) | 1:3 | Dako |
| Anti-CD26 (M-A261) (mc) | 1:50 | PharMingen |
| Anti-CD62L (M7084) (mc) | 1:10 | Dako |
| Anti-CD71 (M-A712) (mc) | 1:100 | PharMingen |
| Anti-CD30 (Ber-H2) (mc) | 1:10 | Dako |
| Anti-CD30 (Ki-1) (mc) | 1:10 | Dako |